Kilroy Mary Kate, Park SoYoung, Feroz Wasim, Patel Hima, Mishra Rosalin, Alanazi Samar, Garrett Joan T
Department of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA.
Cancer Research Scholars Program, College of Allied Health Sciences, University of Cincinnati, Cincinnati, OH 45267, USA.
Cancers (Basel). 2022 Dec 14;14(24):6174. doi: 10.3390/cancers14246174.
In recent years, the third member of the HER family, kinase impaired HER3, has become a target of interest in cancer as there is accumulating evidence that HER3 plays a role in tumor growth and progression. This review focuses on HER3 activation in bladder, breast, colorectal, and lung cancer disease progression. HER3 mutations occur at a rate up to ~10% of tumors dependent on the tumor type. With patient tumors routinely sequenced for gene alterations in recent years, we have focused on HER3 mutations in bladder, breast, colon, and lung cancers particularly in response to targeted therapies and the potential to become a resistance mechanism. There are currently several HER3 targeting drugs in the pipeline, possibly improving outcomes for cancer patients with tumors containing HER3 activation and/or alterations.
近年来，HER家族的第三个成员——激酶功能受损的HER3，已成为癌症领域备受关注的靶点，因为越来越多的证据表明HER3在肿瘤生长和进展中发挥作用。本综述聚焦于HER3激活在膀胱癌、乳腺癌、结直肠癌和肺癌疾病进展中的作用。HER3突变发生率高达肿瘤的10%左右，具体取决于肿瘤类型。近年来随着患者肿瘤常规进行基因改变测序，我们重点关注了膀胱癌、乳腺癌、结肠癌和肺癌中的HER3突变，特别是针对靶向治疗的反应以及其成为耐药机制的可能性。目前有几种HER3靶向药物正在研发中，这可能会改善患有HER3激活和/或改变肿瘤的癌症患者的治疗效果。
